LabCorp/$LH
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About LabCorp
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Ticker
$LH
Sector
Primary listing
NYSE
Employees
70,000
Headquarters
Website
LabCorp Metrics
BasicAdvanced
$21B
24.93
$10.19
0.87
$2.88
1.13%
Price and volume
Market cap
$21B
Beta
0.87
52-week high
$293.72
52-week low
$209.38
Average daily volume
707K
Dividend rate
$2.88
Financial strength
Current ratio
1.551
Quick ratio
1.089
Long term debt to equity
67.013
Total debt to equity
74.944
Dividend payout ratio (TTM)
28.24%
Interest coverage (TTM)
5.87%
Profitability
EBITDA (TTM)
1,963.5
Gross margin (TTM)
28.45%
Net profit margin (TTM)
6.21%
Operating margin (TTM)
9.92%
Effective tax rate (TTM)
22.19%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
4.63%
Return on equity (TTM)
10.14%
Valuation
Price to earnings (TTM)
24.931
Price to revenue (TTM)
1.54
Price to book
2.42
Price to tangible book (TTM)
-13.54
Price to free cash flow (TTM)
15.348
Free cash flow yield (TTM)
6.52%
Free cash flow per share (TTM)
16.546
Dividend yield (TTM)
1.13%
Forward dividend yield
1.13%
Growth
Revenue change (TTM)
8.28%
Earnings per share change (TTM)
98.36%
3-year revenue growth (CAGR)
1.95%
10-year revenue growth (CAGR)
5.88%
3-year earnings per share growth (CAGR)
-18.51%
10-year earnings per share growth (CAGR)
8.18%
3-year dividend per share growth (CAGR)
25.99%
What the Analysts think about LabCorp
Analyst ratings (Buy, Hold, Sell) for LabCorp stock.
Bulls say / Bears say
LabCorp’s Q2 2025 revenue rose 9.5% year-over-year to $3.53 billion, with adjusted EPS of $4.35 beating expectations and prompting an upward revision of full-year adjusted EPS guidance to $16.05–$16.50 and narrowed revenue growth outlook, underscoring strong diagnostic demand and operational execution (Reuters).
LabCorp’s Q3 2025 results delivered 8.5% year-over-year growth in diagnostic lab revenue to $2.77 billion and 8.3% growth in its contract research segment to $799.1 million, with adjusted EPS of $4.18 outperforming estimates and driving an increase in full-year EPS guidance to $16.15–$16.50 despite currency headwinds (Reuters).
CEO Adam Schechter highlighted strategic partnerships with health systems and the launch of specialized diagnostic tests for diseases such as cancer and Alzheimer’s, expanding LabCorp’s high-margin portfolio and strengthening its competitive moat in growth areas (Reuters).
Pursuant to the Protecting Access to Medicare Act, enforcement of PAMA was suspended through 2025, but additional reimbursement cuts of approximately $100 million are slated for 2026 if no legislative relief materializes, posing a material downside risk to LabCorp’s revenues and margins (SEC).
LabCorp trimmed its full-year revenue growth outlook from 7.5%–8.6% to 7.4%–8%, citing adverse foreign exchange movements and acquisition timing, and is divesting roughly $50 million of low-demand drug development revenue through site consolidation, reflecting integration and execution risks (Reuters).
Intensifying competition from Quest Diagnostics and peers managing hospital laboratories threatens to cap LabCorp’s market share in the independent lab space as rivals leverage hospital partnerships to extend their footprint (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2025.
LabCorp Financial Performance
Revenues and expenses
LabCorp Earnings Performance
Company profitability
LabCorp News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for LabCorp stock?
LabCorp (LH) has a market cap of $21B as of November 03, 2025.
What is the P/E ratio for LabCorp stock?
The price to earnings (P/E) ratio for LabCorp (LH) stock is 24.93 as of November 03, 2025.
Does LabCorp stock pay dividends?
Yes, the LabCorp (LH) stock pays dividends to shareholders. As of November 03, 2025, the dividend rate is $2.88 and the yield is 1.13%. LabCorp has a payout ratio of 28.24% on a trailing twelve-month basis.
When is the next LabCorp dividend payment date?
The next LabCorp (LH) dividend payment is scheduled for December 11, 2025.
What is the beta indicator for LabCorp?
LabCorp (LH) has a beta rating of 0.87. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.